On September 10, 2025, BioXcel Therapeutics, Inc. announced positive data from its SERENITY At-Home Phase 3 trial of BXCL501 for treating agitation in bipolar disorders and schizophrenia, showing significant improvement with 50% overall resolution of agitation compared to 33% on placebo.